Laropiprant is a drug used to reduce the risk of cardiovascular events such as heart attack and stroke in people with high cholesterol. It is a nicotinic acid receptor antagonist, meaning it works by blocking the effects of the hormone nicotinic acid, which causes the body to produce more cholesterol. It is typically used in combination with a statin, a type of drug that lowers cholesterol levels. Laropiprant can help reduce the risk of cardiovascular events in people at high risk for them, such as those with high cholesterol, diabetes, and a history of smoking.
Laropiprant is a medication currently under development, undergoing clinical trials for its potential use in treating cholestatic liver diseases [1, 2]. Here's a breakdown of what we know so far:
- What is laropiprant being studied for?
Laropiprant is primarily being investigated as a treatment for cholestatic liver diseases, a group of conditions that affect bile flow from the liver. Here are two specific conditions where laropiprant is being studied:
- How laropiprant might work:
The exact mechanism of action for laropiprant is still under investigation, but it's believed to work by inhibiting a specific protein called ileal bile acid transporter (IBAT) [2]. IBAT is involved in the reabsorption of bile acids in the intestine. By inhibiting IBAT, laropiprant may increase the excretion of bile acids through the feces, potentially reducing their buildup in the liver and improving liver function [2, 5].
- Current status:
Laropiprant is in the clinical trial phase, and more research is needed to confirm its long-term safety and efficacy for treating cholestatic liver diseases. It has not yet received final approval from regulatory agencies for widespread use [2].
- Important things to consider:
- Laropiprant is not yet a commercially available medication.
- More research is needed to confirm its long-term safety and efficacy for cholestatic liver diseases.
- If you have a cholestatic liver disease, it's important to consult with your doctor about currently approved treatment options.
Here are some additional points to note:
- Laropiprant is typically being investigated in combination with other medications for cholestatic liver diseases [2].
- It may be administered orally, offering a potentially convenient way to manage the condition if approved for use [2].